Jun 03, 2026
NewLimit Series C: Armstrong-Backed Longevity Startup Raises $435M
FintechTechnologybiotech fundingBrian Armstrongcrypto foundersepigenetic reprogrammingFounders Fundhuman trialslongevity biotechNewLimitSeries C
TLDR: NewLimit Series C raised $435M led by Founders Fund for longevity biotech expansion and clinical readiness. Startup targets epigenetic reprogramming therapies aimed at restoring youthful function in aged human cells. First-in-human trials for lead liver cell program are planned for next year after recent breakthrough results. Funding brings major VC backing as NewLimit scales [...]
The post NewLimit Series C: Armstrong-Backed Longevity Startup Raises $435M appeared first on Blockonomi.
Source: Blockonomi →Related News
- 13 hours ago
Coinbase-Backed Ethereum Network Base Recovers After Block Production Issue
- 1 day ago
Researcher Throws Cold Water on Microsoft Quantum Claims
- 1 day ago
How Provably Fair Technology Works — And How to Verify Any Crypto Casino Bet
- 1 day ago
Standard Chartered Backs Aave on Growing Tokenization Trend
- 1 day ago
INFINIOS and Circle Partner to Expand Digital Finance Infrastructure Across the...